The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Open accessAbstract
The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitizes cells to a CSNK1 inhibitor relative to cells with two intact alleles. In addition, we identified recurrent somatic mutations in CSNK1A1 on the nondeleted allele of patients with del(5q) MDS. These studies demonstrate that CSNK1A1 plays a central role in the biology of del(5q) MDS and is a promising therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CK1α is essential for the survival of hematopoietic stem cells, and heterozygous deletion of its gene in del(5q) myelodysplastic syndrome provides a therapeutic window for eliminating the malignant stem cell clone (10).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, lenalidomide-induced degradation of the remaining cK1α mimics biallelic loss of CSNK1A1 which triggers p53 activation, enhances apoptosis and leads to clonal arrest of the 5q-deleted population which ultimately drives disease regression (wei et al. 2009;Schneider et al. 2014;Krönke et al. 2015).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Schneider et al. 2014
Experimental — accuracy not yet measuredIn the citing paper
“Accordingly, mutations in TP53 lead to resistance to lenalidomide in patients with MDS97,98 (FIG. 3).”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [98]
In the citing paper
“Consistent with these experimental findings, resistance to lenalidomide and disease progression are associated with an increased frequency of TP53 mutations in patients with del(5q) MDS98,161,162.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,954
WHO classification of haematolymphoid tumours
Gaillard, F., & Gerstenmaier, J. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,763
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato‐Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,257
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 953
Self-citationHaase, D. T., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kündgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082404 · Cited by 796
The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
Wang, J. Y., Krivtsov, A. V., Sinha, A. U., North, T. E., Goessling, W., Feng, Z., Zon, L. I., & Armstrong, S. A. (2010) · Science · doi:10.1126/science.1186624 · Cited by 777
Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 736
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Shirai, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2011) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 604
Cited by
Sorted by citations
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Self-citationThe genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.112 · Cited by 706
Self-citationStructural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537
“CK1a is essential for the survival of hematopoietic stem cells, and heterozygous deletion of its gene in del(5q) myelodysplastic syndrome provides a therapeutic window for eliminating the malignant stem cell clone (10).”
BackgroundSelf-citationCazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 508
Darman, R. B., Seiler, M., Agrawal, A. A., Lim, K., Peng, S., Aird, D. R., Bailey, S., Bhavsar, E. B., Chan, B., Colla, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.053 · Cited by 472
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Beau, M. M. L. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.60 · Cited by 434
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 428
Ogawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 382
Malcovati, L., Stevenson, K. E., Papaemmanuil, E., Neuberg, D. S., Bejar, R. L., Boultwood, J., Bowen, D., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 304
Self-citationRps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Schneider, R. K., Schenone, M., Ferreira, M. S. V., Kramann, R., Joyce, C. E., Hartigan, C. R., Beier, F., Brümmendorf, T. H., Germing, U., Platzbecker, U., et al. (2016) · Nature Medicine · doi:10.1038/nm.4047 · Cited by 246
Self-citationThe novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Self-citationTargeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
How Ribosomes Translate Cancer
Sulima, S. O., Hofman, I. J., Keersmaecker, K. D., & Dinman, J. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0550 · Cited by 185
A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity
Chung, K.-J., Chatzigeorgiou, A., Economopoulou, M., Garcia-Martin, R., Alexaki, V. I., Mitroulis, I., Nati, M., Gebler, J., Ziemssen, T., Goelz, S. E., et al. (2017) · Nature Immunology · doi:10.1038/ni.3728 · Cited by 175
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 184
Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-03-657379 · Cited by 158
Minzel, W., Venkatachalam, A., Fink, A., Hung, E., Brachya, G., Burstain, I., Shaham, M., Rivlin, A., Omer, I., Zinger, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.045 · Cited by 161
Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 156
Self-citationCK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy
Cai, J., Li, R., Xu, X., Zhang, L., Lian, R., Fang, L., Huang, Y., Feng, X., Liu, X., Xu, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0065-8 · Cited by 146
Megakaryocyte and polyploidization
Mazzi, S., Lordier, L., Debili, N., Raslová, H., & Vainchenker, W. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.10.001 · Cited by 154
Collins, I., Wang, H., Caldwell, J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 139
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Self-citationCrbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Self-citationCasein kinase 1α: biological mechanisms and theranostic potential
Jiang, S., Zhang, M., Sun, J., & Yang, X. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0236-z · Cited by 130
Pharmacological inhibition of the transcription factor PU.1 in leukemia
Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92504 · Cited by 120
NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly
Niu, T., de Rosny, C., Chautard, S., Rey, A., Patoli, D., Groslambert, M., Cosson, C., Lagrange, B., Zhang, Z., Visvikis, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26142-w · Cited by 130
The molecular pathogenesis of the myelodysplastic syndromes
Pellagatti, A., & Boultwood, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12515 · Cited by 120
Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141898 · Cited by 111
Genetic abnormalities and pathophysiology of MDS
Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 111
The phosphorylation switch that regulates ticking of the circadian clock
Narasimamurthy, R., & Virshup, D. M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.006 · Cited by 105
Mercurio, A., Adriani, G., Catalano, A. A., Carocci, A., Rao, L., Lentini, G., Cavalluzzi, M. M., Franchini, C., Vacca, A., & Corbo, F. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170601074646 · Cited by 82
The genetic and molecular pathogenesis of myelodysplastic syndromes
Shallis, R. M., Ahmad, R., & Zeidan, A. M. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13092 · Cited by 76
Emadali, A., Hoghoughi, N., Duley, S., Hajmirza, A., Verhoeyen, E., Cosset, F., Bertrand, P., Roumier, C., Roggy, A., Suchaud-Martin, C., et al. (2016) · Blood · doi:10.1182/blood-2015-09-671040 · Cited by 76
Genomic landscape of megakaryopoiesis and platelet function defects
Bianchi, E., Norfo, R., Pennucci, V., Zini, R., & Manfredini, R. (2016) · Blood · doi:10.1182/blood-2015-07-607952 · Cited by 70
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
Janovská, P., Normant, E., Miskin, H. P., & Bryja, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239026 · Cited by 74
Clonal hematopoiesis in the inherited bone marrow failure syndromes
Tsai, F. D., & Lindsley, R. C. (2020) · Blood · doi:10.1182/blood.2019000990 · Cited by 69
Shi, Q., & Chen, L. (2017) · Journal of Immunology Research · doi:10.1155/2017/9130608 · Cited by 63
Nishiguchi, G., Mascibroda, L. G., Young, S. M., Caine, E. A., Abdelhamed, S., Kooijman, J. J., Miller, D. J., Das, S., McGowan, K., Mayasundari, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44698-1 · Cited by 57
Cereblon in health and disease
Kim, H. K., Ko, T. H., Nyamaa, B., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Park, C., Nilius, B., & Han, J. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1854-1 · Cited by 55
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells
Park, S.-M., Miyamoto, D. K., Han, G. Y. Q., Chan, M., Curnutt, N. M., Tran, N. L., Velleca, A., Kim, J. H., Schurer, A., Chang, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.010 · Cited by 56
Anemia as the Main Manifestation of Myelodysplastic Syndromes
Santini, V. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.06.002 · Cited by 52
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 51
Ribezzo, F., Snoeren, I. A. M., Ziegler, S., Stoelben, J., Olofsen, P. A., Henic, A., Ferreira, M. V., Chen, S., Stalmann, U. S. A., Buesche, G., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0350-3 · Cited by 51
Self-citationA decade of progress in myelodysplastic syndrome with chromosome 5q deletion
List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia · doi:10.1038/s41375-018-0029-9 · Cited by 49
Self-citationMegakaryocyte polyploidization: role in platelet production
Vainchenker, W., & Raslová, H. (2019) · Platelets · doi:10.1080/09537104.2019.1667497 · Cited by 49
Qiu, J., Zhou, B., Thol, F. R., Zhou, Y., Chen, L., Shao, C., DeBoever, C., Hou, J., Li, H., Chaturvedi, A., et al. (2016) · RNA · doi:10.1261/rna.056101.116 · Cited by 48
Self-citationZini, R., Guglielmelli, P., Pietra, D., Rumi, E., Rossi, C., Rontauroli, S., Genovese, E., Fanelli, T., Calabresi, L., Bianchi, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0010-2 · Cited by 49
Mechanisms of lenalidomide sensitivity and resistance
Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 48
Recurrent genetic defects on chromosome 5q in myeloid neoplasms
Hosono, N., Makishima, H., Mahfouz, R. Z., Przychodzen, B. P., Yoshida, K., Jerez, A., LaFramboise, T., Polprasert, C., Clemente, M. J., Shiraishi, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14130 · Cited by 45
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Talati, C., Sallman, D. A., & List, A. F. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.003 · Cited by 45
Patil, A., Manzano, M., & Gottwein, E. (2018) · Blood · doi:10.1182/blood-2018-01-828418 · Cited by 45
Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis
Zhao, Z., Chen, C.-C., Rillahan, C. D., Shen, R., Kitzing, T. M., McNerney, M. E., Díaz-Flores, E., Zuber, J. A., Shannon, K., Beau, M. M. L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3251 · Cited by 43
Molecular pathogenesis of myelodysplastic syndromes with deletion 5q
Lee, J.-H., List, A. F., & Sallman, D. A. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13207 · Cited by 44
Ferreira, M. S. V., Bergmann, C., Bodensiek, I., Peukert, K., Abert, J., Kramann, R., Kachel, P., Rath, B., Rütten, S., Knüchel, R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0234-9 · Cited by 42
Self-citationMolecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
Negoro, E., Radivoyevitch, T., Polprasert, C., Ademà, V., Hosono, N., Makishima, H., Przychodzen, B. P., Hirsch, C., Clemente, M. J., Nazha, A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.228 · Cited by 43
Self-citationTP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Shah, M. V., Arber, D. A., & Hiwase, D. (2025) · American Journal of Hematology · doi:10.1002/ajh.27655 · Cited by 43
RECENT ADVANCES IN THE 5Q- SYNDROME
Pellagatti, A., & Boultwood, J. (2015) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2015.037 · Cited by 40
Manni, S., Carrino, M., & Piazza, F. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0529-5 · Cited by 40
Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells
Liu, T., Krysiak, K., Shirai, C. L., Kim, S. P., Shao, J., Ndonwi, M., & Walter, M. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170470 · Cited by 36
CK1α ablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation
Chang, C., Kuo, C.-J., Ito, T., Su, Y.-Y., Jiang, S., Chiu, M., Lin, Y., Nist, A., Mernberger, M., Stiewe, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702763114 · Cited by 35
Glycogen synthase kinase‐3 and alternative splicing
Liu, X., & Klein, P. S. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1501 · Cited by 38
Role of reactive oxygen species in myelodysplastic syndromes
Jing, Q., Zhou, C., Zhang, J., Zhang, P., Wu, Y., Zhou, J., Tong, X., Li, Y., Du, J., & Wang, Y. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00570-0 · Cited by 33
Takai, A., Dang, H. T., Oishi, N., Khatib, S. A., Martin, S. P., Dominguez, D. A., Luo, J., Bagni, R., Wu, X., Powell, K., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3015 · Cited by 32
List, A. F., Sun, Z., Verma, A. K., Bennett, J. M., Komrokji, R. S., McGraw, K. L., Maciejewski, J. P., Altman, J. K., Cheema, P. S., Claxton, D. F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01691 · Cited by 32
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 30
Self-citationTIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease
Niederkorn, M., Agarwal, P., & Starczynowski, D. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.08.010 · Cited by 31
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 29
Bereshchenko, O., Re, O. L., Nikulenkov, F., Flamini, S., Kotašková, J., Mazza, T., Pannérer, M.-M. L., Buschbeck, M., Giallongo, C., Palumbo, G. A., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0724-z · Cited by 28
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 31
Have we reached a molecular era in myelodysplastic syndromes?
Voso, M. T., & Gurnari, C. (2021) · Hematology · doi:10.1182/hematology.2021000276 · Cited by 27
Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts
Malcovati, L., & Cazzola, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14215 · Cited by 29
Primary Myelodysplastic Syndromes
Gangat, N., Patnaik, M. M., Begna, K. H., Kourelis, T., Al‐Kali, A., Elliott, M. A., Hogan, W. J., Letendre, L., Litzow, M. R., Knudson, R. A., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.08.022 · Cited by 27
Ganguly, B. B., Banerjee, D., & Agarwal, M. B. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.10.001 · Cited by 26
Chen, Z., Dhruv, H., Zhang, X., Rej, R. K., Bai, L., McEachern, D., Kirchhoff, P. D., Nagilla, R., Jolivette, L. J., Rice, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58431-z · Cited by 28
Targeting the Microenvironment in MDS: The Final Frontier
Teodorescu, P., Paşca, S., Dima, D. M., Tomuleasa, C., & Ghiaur, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01044 · Cited by 25
Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
Spinello, Z., Fregnani, A., Tubi, L. Q., Trentin, L., Piazza, F., & Manni, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073716 · Cited by 29
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences
Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 26
Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 26
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
Bello, E., Pellagatti, A., Shaw, J. M., Mecucci, C., Kušec, R., Killick, S. B., Giagounidis, A. A. N., Raynaud, S., Calasanz, M. J., Fenaux, P., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13563 · Cited by 25
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26
Heuser, M., Meggendorfer, M., Cruz, M. M. A., Fabisch, J., Klesse, S., Köhler, L., Göhring, G., Ganster, C., Shirneshan, K., Gutermuth, A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.49 · Cited by 24
Smith, A., Kulasekararaj, A. G., Jiang, J., Mian, S. A., Mohamedali, A. M., Gäken, J. A., Ireland, R. M., Czepulkowski, B. H., Best, S., & Mufti, G. J. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00050-2 · Cited by 24
Suzuki, Y., Tomita, A., Nakamura, F., Iriyama, C., Shirahata‐Adachi, M., Shimada, K., Akashi, A., Ishikawa, Y., Kaneda, N., & Kiyoi, H. (2016) · Cancer Science · doi:10.1111/cas.12994 · Cited by 23
Liu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 25
Targeting TP53 Mutations in Myelodysplastic Syndromes
Hunter, A. M., & Sallman, D. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.004 · Cited by 25
β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q)
Li, L., Sheng, Y., Li, W., Hu, C., Mittal, N., Tohyama, K., Seba, A., Zhao, Y., Ozer, H., Zhu, T., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0202 · Cited by 20
Maru, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-1757-7_11 · Cited by 25
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias
Raundhal, M. R., Ghosh, S., Myers, S. A., Cuoco, M. S., Singer, M., Carr, S. A., Waikar, S. S., Bonventre, J. V., Ritz, J., Stone, R. M., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00895-4 · Cited by 20
Biology of Erythropoiesis, Erythroid Differentiation, and Maturation
Papayannopoulou, T., & Migliaccio, A. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00026-3 · Cited by 21
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
The Coming of Age of Preclinical Models of MDS
Liu, W., Teodorescu, P., Halene, S., & Ghiaur, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.815037 · Cited by 20
Lee, E.-J., & Zeidan, A. M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1016905 · Cited by 19
Stoner, S. A., Yan, M., Liu, K. T. H., Arimoto, K., Shima, T., Wang, H., Johnson, D. T., Bejar, R. L., Jamieson, C. H. M., Guan, K., et al. (2019) · Blood · doi:10.1182/blood.2019000170 · Cited by 19
Self-citationPathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
Ademà, V., Palomo, L., Walter, W., Mallo, M., Hütter, S., Framboise, T. L., Arenillas, L., Meggendorfer, M., Radivoyevitch, T., Xicoy, B., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104059 · Cited by 18
Self-citationTargeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
Woll, P. S., Yoshizato, T., Hellström‐Lindberg, E., Fioretos, T., Ebert, B. L., & Jacobsen, S. E. W. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13535 · Cited by 15
Self-citationGenetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Nardi, V., & Hasserjian, R. P. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.10.004 · Cited by 19
Rasmussen, B. E. H., Göhring, G., Bernard, E., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H. G., Dybedal, I., Grønbæk, K., Ejerblad, E., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01537-w · Cited by 18
The Genetic Architecture of Murine Glutathione Transferases
Lu, L., Pandey, A. K., Houseal, M. T., & Mulligan, M. K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148230 · Cited by 16
Metadata
- Authors
- Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., Bejar, R., Solé, F., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Universitat Autònoma de Barcelona (ES)
- University of California San Diego (US)
- Broad Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 26
- Issue
- 4
- Pages
- 509-520
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4199102
- OpenAlex
- W2081870738
- Cited by
- 188
- References
- 52
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 5 · 2022: 16 · 2021: 18 · 2020: 16 · 2019: 13 · 2018: 20 · 2017: 24 · 2016: 22 · 2015: 19 · 2014: 1
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Harvard Stem Cell Institute
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Cancer Institute (P30CA023100, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK091360)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- CSNK1A1, del(5q) myelodysplastic syndrome, tumor suppressor, haploinsufficiency, hematopoietic stem cells, competitive repopulation, conditional knockout mouse model, somatic mutations, therapeutic target
- MeSH terms
- Aged, Animals, Base Sequence, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Flow Cytometry, Humans, Male, Mutation, Myelodysplastic Syndromes, Polymerase Chain Reaction, DNA Primers, Casein Kinase I, Mice, Young Adult, Haploinsufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
